French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful
"The commitment from Wellington Partners, one of the most reputable life science investors in Europe, is further endorsement of Genticel's therapeutic HPV vaccine development," said Benedikt Timmerman, founder and CEO of Genticel, in a statement.
Wellington Partners invests €4m in HPV vaccine developer Genticel
Genticel Inks Over $20m Led by Wellington
Wellington Partners leads € 18.2 million financing round at Genticel
View full post on hpv – Google News